Calcific uremic arteriolopathy should be treated conservatively

Seminars in Dialysis

Volumn 23, Issue 1, 2010, Pages 34-37

  Courtney, Mark J ^a   Pannu, Neesh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERIOLE; CALCINOSIS; HUMAN; REVIEW; UREMIA; VASCULAR DISEASE;

ARTERIOLES; CALCINOSIS; HUMANS; UREMIA; VASCULAR DISEASES;

EID: 77950325850     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2009.00655.x     Document Type: Review

References (27)

1. Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, Stehman-Breen CO. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001, 60:324-332.
2. Wilmer WA, Magro CA. Calciphylaxis: emerging concepts in prevention, diagnosis and treatment. Semin Dial 2002, 15:172-186.
3. Rogers NM, Teubner DJO, Coates PTH. Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Sem Dial 2007, 20:150-157.
4. Weenig RH. Pathogenesis of calciphylaxis: Hans Selye to nuclear factor k-B J Am Acad Dermatol 2008, 58:458-471.
5. Rogers N, Coates PTH. Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens 2008, 17:629-634.
6. Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R. Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease and calciphylaxis-calcific uremic arteriolopathy the emerging role of sodium thiosulphate. Cardiovasc Diabetol 2005, 4:4-25.
7. Weenig RH, Sewell LD, Davis MDP, McCarthy JT, Pittelkow MR. Calciphylaxis: natural history, risk factor analysis and outcome. J Am Acad Dermatol 2007, 56:569-579.
8. Kang AS, McCarthy JT, Rowland C, Farley DR, Van Heerden JA. Is calciphylaxis best treated surgically or medically? Surgery 2000, 128:967-972.
9. Wilmer W, Voroshilova O, Singh I, Middendorf DF, Cosio F. Transcutaneous oxygen tension in patients with calciphylaxis. Am J Kidney Dis 2001, 37:797-806.
10. Babior B. Oxygen dependent microbial killing by phagocytes. N Engl J Med 1978, 298:659-668.
11. Kim B, Kim H, Park S, Cha JS, Yufit T, Kim SJ. Fibroblasts from chronic wounds show altered TGF-β signaling and decreased TGF-β type II receptor expression. J Cell Physiol 2003, 195:331-336.
12. Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. N Engl J Med 1996, 334:1642-1648.
13. Narkowicz C, Vial J, McCartney P. Hyperbaric oxygen increases free radical levels in the blood of humans. Free Radic Res Comm 1993, 19:71-80.
14. Basile C, Montanaro A, Masi M, Pati G, De Maio P, Gismondi A. Hyperbaric oxygen for calcific uremic arteriolopathy: a case series. J Nephrol 2002, 15:676.
15. Podymow T, Wherrett C, Burns KD. Hyperbaric oxygen in the treatment of calciphylaxis: a case series. Nephrol Dial Transplant 2001, 16:2176-2180.
16. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002, 61:2210-2217.
17. Chan MR, Yevzlin AS, Hinsham M, Jaffrey JB. Calciphylaxis responsive to lanthanum carbonate (FOSRENOL) therapy. WMJ 2008, 107:335-338.
18. Llach F. The evolving pattern of calciphylaxis: therapeutic considerations. Nephrol Dial Transplant 2001, 16:448-451.
19. Don BR, Chin AI. A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. Clin Nephrol 2003, 59:463-470.
20. Duffy A, Schurr M, Warner T, Chen H. Long-term outcomes in patients with calciphylaxis from hyperparathyroidism. Ann Surg Oncol 2006, 13:96-102.
21. Chan YL, Mahony JF, Turner JJ, Posen S. The vascular lesions associated with skin necrosis in renal disease. Br J Dermatol 1983, 109:85-95.
22. Mawad HW, Sawaya BP, Sarin R, Malluche HH. Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin Nephrol 1999, 52:160-166.
23. Raymond CB, Wazny LD. Sodium thiosulphate, bisphosphanates and cinacalcet for treatment of calciphylaxis. Am J Health Syst Pharm 2008, 65:1419-1429.
24. Coates T, Kirkland GS, Dymock RB, Murphy BF, Brealey JK, Mathew TH, Disney AP. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 1998, 32:384-391.
25. Ciccone JS, Petronis J, Embert C, Spector D. Successful treatment of calciphylaxis with intravenous sodium thiosulphate. Am J Kidney Dis 2004, 43:1104-1108.
26. Hayden MR, Goldsmith D, Sowers JR, Khanna R. Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosulphate. Int Urol Nephrol 2008, 40:443-451.
27. Subramaniam K, Wallace H, Sinniah R, Saker B. Complete resolution of recurrent calciphylaxis with long-term intravenous sodium thiosulphate. Austral J Dermatol 2008, 49:30-34.